Table 4.
Relationship between -2548 G/A LEP and Q223R LEPR polymorphisms with pathological indicators in patients with breast cancer.
| Pathological feature | Number of patients (%) | p value | |
|---|---|---|---|
| LEP (-2548) G/A | GA + AA | GG | |
|
| |||
| ER | |||
| Negative | 12 (92.3)∗ | 1 (7.7) | 0.65 |
| Positive | 26 (81.3) | 6 (18.8) | |
| PR | |||
| Negative | 13 (86.7) | 2 (13.3) | 1.00 |
| Positive | 25 (83.3) | 5 (16.7) | |
| HER2 | |||
| Negative | 27 (90) | 3 (10) | 0.19 |
| Positive | 11 (73.3) | 4 (26.7) | |
| Stage | |||
| I & II | 21 (91.3) | 2 (8.7) | 0.24 |
| III & IV | 17 (72.28) | 5 (22.73) | |
|
| |||
| LEPR Q223R | QR + RR | ||
|
| |||
| ER | |||
| Negative | 4 (30.8) | 9 (69.2) | 0.5 |
| Positive | 15 (46.9) | 17 (56.7) | |
| PR | |||
| Negative | 6 (40) | 9 (60) | 1.00 |
| Positive | 25 (83.3) | 17 (56.7) | |
| HER2 | |||
| Negative | 14 (46.7) | 16 (53.3) | 0.5 |
| Positive | 5 (33.3) | 10 (66.7) | |
| Stage | |||
| I & II | 10 (43.4) | 13 (56.5) | 1.00 |
| III & IV | 9 (41) | 13 (59) | |
∗Numbers in parentheses represent the percentage.